Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | MB-49 |
| Species | Mouse |
| Cat.No | ABC-TC223S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Bladder |
| Disease | Urothelial Cancer |
| Storage | Liquid Nitrogen |
| Product Type | Mouse Bladder Cancer Cell Lines |
MB49 is a urothelial carcinoma cell line derived from a male C57BL/6 mouse by exposing primary bladder cells to DMBA (7,12-dimethylbenz[a]anthracene) for 24 hours, followed by culturing. Despite its male origin, MB49 lacks the Y-chromosome and male-specific antigen expression. In culture, MB49 cells exhibit a fibroblast-like morphology and grow in suspension with a moderate proliferation rate. This characteristic limits the immune response within the tumor microenvironment. No viral properties, such as HPV or EBV, are associated with MB49 cells. This makes it a useful model for studying urothelial carcinoma and immunotherapy resistance.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
The MB49 mouse urothelial carcinoma cell line is widely used to model bladder cancer in vitro and in vivo. With its potential as an immuno-oncology model, MB49 is widely applied in drug screening and immunotherapy development. Its responsiveness to checkpoint inhibitor therapy and costimulatory antibody therapy enables exploration of combinatorial strategies with checkpoint and costimulatory agents. Therefore, MB49 offers a versatile platform for studying the efficacy and mechanisms of immunotherapies, contributing to advancements in cancer treatment strategies.
